Cancer Chemotherapy: International Symposium Proceedings
Proceedings of the 6th Nagoya International Symposium on Cancer Treatment, Nagoya, Japan, 14-15 October 1990
Published in December 1991
Book
Hardback
272 pages
978-0-444-89260-7 (ISBN)
Description
Today, acute leukemia, malignant lymphoma and several other cancers are regarded as curable diseases. As a result, the last 10 years has seen remarkable progress in early diagnosis and treatment of a range of cancers. Treatment is based mainly on chemotherapeutic schedules that include combinations of new agents. The past five volumes of proceedings of the Nagoya International Symposia on Cancer Treatment have covered progress in these agents and their clinical applications. The main topic of this volume is minimal residual disease. Early detection and treatment of minimal residual disease during complete remission of acute leukemia, lymphona, and solid tumors after surgical treatment are the most important problems to overcome in obtaining cure. Even in advanced cancer, cure by treatment is dependent on a reduction in the numbers of cancer cells. Minimal residual cells are eradicated by chemotherapy, radiotherapy and surgical treatment. Further, progress in immunological and biochemical fields has enabled detection of minimal residual cells using monoclonal antibodies, in vitro DNA amplification of the immunoglobulin hypervariable sequences, and polymerase chain reactions.
Today, acute leukemia, malignant lymphoma and several other cancers are regarded as curable diseases. As a result, the last 10 years has seen remarkable progress in early diagnosis and treatment of a range of cancers. Treatment is based mainly on chemotherapeutic schedules that include combinations of new agents. The past five volumes of proceedings of the Nagoya International Symposia on Cancer Treatment have covered progress in these agents and their clinical applications. The main topic of this volume is minimal residual disease. Early detection and treatment of minimal residual disease during complete remission of acute leukemia, lymphona, and solid tumors after surgical treatment are the most important problems to overcome in obtaining cure. Even in advanced cancer, cure by treatment is dependent on a reduction in the numbers of cancer cells. Minimal residual cells are eradicated by chemotherapy, radiotherapy and surgical treatment. Further, progress in immunological and biochemical fields has enabled detection of minimal residual cells using monoclonal antibodies, in vitro DNA amplification of the immunoglobulin hypervariable sequences, and polymerase chain reactions.
Today, acute leukemia, malignant lymphoma and several other cancers are regarded as curable diseases. As a result, the last 10 years has seen remarkable progress in early diagnosis and treatment of a range of cancers. Treatment is based mainly on chemotherapeutic schedules that include combinations of new agents. The past five volumes of proceedings of the Nagoya International Symposia on Cancer Treatment have covered progress in these agents and their clinical applications. The main topic of this volume is minimal residual disease. Early detection and treatment of minimal residual disease during complete remission of acute leukemia, lymphona, and solid tumors after surgical treatment are the most important problems to overcome in obtaining cure. Even in advanced cancer, cure by treatment is dependent on a reduction in the numbers of cancer cells. Minimal residual cells are eradicated by chemotherapy, radiotherapy and surgical treatment. Further, progress in immunological and biochemical fields has enabled detection of minimal residual cells using monoclonal antibodies, in vitro DNA amplification of the immunoglobulin hypervariable sequences, and polymerase chain reactions.
More details
Series
Language
English
Place of publication
Oxford
United Kingdom
Publishing group
Elsevier Science & Technology
Target group
College/higher education
Professional and scholarly
Dimensions
Height: 230 mm
Weight
760 gr
ISBN-13
978-0-444-89260-7 (9780444892607)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Content
Keynote address. Bone marrow transplantation for hematologic malignancies (G.W. Santos). I. Detection of minimal residual disease. Detection of minimal residual disease in leukemias and lymphomas by immunocytology using monoclonal antibodies (M. Pfreundschuh, M. Schwonzen). Use of an oligonucleotide and peptide for diagnosis of digestive tract cancers (K. Imai et al.). Discussion. Detection of minimal residual leukemia by polymerase chain reaction (PCR) strategies (C.R. Bartram et al.). In situ hybridization using T-T dimerized non-radioactive probes (P.K. Nakane, T. Koji, M. Shin). Polymerase chain reaction for the detection of minimal residual B-cell clones using diversity of complementarity determining region (CDR) III (T. Naoe, H. Kiyoi, R. Ohno). Discussion. II. Intensive chemotherapy with bone narrow transplantation. Treatment of leukemia with bone marrow transplantation (P.B. McGlave). Recent results of bone marrow transplantation (BMT) in Japan (T. Masaoka). Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia using monoclonal antibody-purged bone marrow (S. Kojima et al.). Discussion. Bone marrow transplantation from donors other than HLA identical siblings (P.G. Beatty). Bone marrow transplantation from donors other than HLA identical siblings: Comparison between Japanese and US sample populations (Y. Morishima et al.). Discussion. Autologous bone marrow transplantation for children with cancer (M. Ohira, J.Takayama, R. Tanaka, S. Yajima). High-dose chemotherapy with autologous hematopoietic stem cell transplant for cancers (T. Mukaiyama, M. Ogawa). Discussion. III. Intensive chemotherapy with colony stimulating factor. Improved delivery of high dose chemotherapy to chemosensitive tumors with G-CSF (G. Morstyn). Dose intensive chemotherapy with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in lung cancer (M. Fukuoka et al.). Clinical application of rhG-CSF in the fields of chemotherapy and bone marrow transplantation (H. Kodo). Role of granulocyte colony stimulating factor after intensive chemotherapy or bone marrow transplantation in acute leukemia (R. Ohno). Discussion. Special lecture. Biologic homogeneity and the search for cancer cures (M.A. Friedman). Discussion. IV. Biochemical modulation of chemotherapy in gastrointestinal cancer. Biochemical modulation of 5-fluorouracil with leucovorin (A.J. Schutt). Sequential methotrexate-fluorouracil (MTX-5-FU) therapy for advanced gastrointestinal cancer (T. Abe). High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer (T. Sasaki). Discussion. Biochemical modulation of 5-fluorouracil with interferons: An overview (S. Wadler, E.L. Schwartz). A group study of UFT plus mitomycin C for advanced gastric cancer (Japanese Advanced Gastric Cancer Chemotherapy Study Group; Chairperson: M. Kurihara). Potentiation of anticancer drug cytotoxity by dipyridamole (Y. Maehara). Discussion. V.